Sexual Problems During the First 2 Years of Adjuvant Treatment with Aromatase Inhibitors
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Introduction: Sexual dysfunction has only recently been recognized as a highly prevalent side effect of adjuvant aromatase inhibitor (AI) therapy for breast cancer. Aims: A cross-sectional survey using standardized measures of female sexual function was designed to provide a detailed view of sexual problems during the first 2 years of adjuvant AI therapy and secondarily to examine whether sexual dysfunction leads to nonadherence to this therapy. Methods: Questionnaires were mailed to all 296 women in a breast oncology registry who had been prescribed a first-time AI for localized breast cancer 18–24 months previously. Main Outcome Measures: Items assessed medication adherence, demographic, and medical information. Scales included the Female Sexual Function Index, the Menopausal Sexual Interest Questionnaire, the Female Sexual Distress Scale-Revised, the Breast Cancer Prevention Trial Eight Symptom Scale to assess menopausal symptoms, and the Merck Adherence Estimator®. Results: Questionnaires were returned by 129 of 296 eligible women (43.6%). Respondents were 81% non-Hispanic white with a mean age of 63 and 48% had at least a college degree. Only 15.5% were nonadherent. Ninety-three percent of women scored as dysfunctional on the Female Sexual Function Index, and 75% of dysfunctional women were distressed about sexual problems. Although only 52% of women were sexually active when starting their AI, 79% of this group developed a new sexual problem. Fifty-two percent took action to resolve it, including 24% who stopped partner sex, 13% who changed hormone therapies, and 6% who began a vaginal estrogen. Scores on the Adherence Estimator (beliefs about efficacy, value, and cost of medication) were significantly associated with adherence (P = 0.0301) but sexual function was not. Conclusions: The great majority of women taking AIs have sexual dysfunction that is distressing and difficult to resolve. Most continue their AI therapy, but a large minority cease sexual activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The female sexual function index (FSFI): cross-validation and development of clinical cutoff scores
WIEGEL, M., MESTON, C., & ROSEN, R. (2005) · Journal of Sex & Marital Therapy · doi:10.1080/00926230590475206 · Cited by 2,396
Sexual Problems and Distress in United States Women: Prevalence and Correlates
Shifren, J. L., Monz, B. U., Russo, P. A., Segreti, A., & Johannes, C. B. (2008) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e3181898cdb · Cited by 1,394 · cited 1×
“Women's distress about having a sexual problem decreases sharply with age and lack of a partner [22,23].”
BackgroundExemestane for Breast-Cancer Prevention in Postmenopausal Women
Goss, P. E., Ingle, J. N., Alés-Martínez, J. E., Cheung, A. M., Chlebowski, R. T., Wactawski-Wende, J., McTiernan, A., Robbins, J., Johnson, K. C., Martin, L. W., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103507 · Cited by 970 · cited 1×
“Two recent randomized trials have also demonstrated AIs’ effectiveness for primary prevention in postmenopausal women at high risk for breast cancer [2,3].”
BackgroundDeRogatis, L., Clayton, A., Lewis-D'Agostino, D., Wunderlich, G., & Fu, Y. (2008) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2007.00672.x · Cited by 740 · cited 1×
“Of 75 women with abnormal FSFI total scores, 75% met the criterion of distress about their dysfunction on the FSD-R by scoring 11 or higher [37].”
BackgroundMurphy, C. C., Bartholomew, L. K., Carpentier, M. Y., Bluethmann, S. M., & Vernon, S. W. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2114-5 · Cited by 708 · cited 8×
“We also relied on women's self-reports of adherence, which may underestimate actual rates [15,27].”
BackgroundMethodInfluentialCuzick, J., Sestak, I., Forbes, J. F., Dowsett, M., Knox, J., Cawthorn, S., Saunders, C., Roche, N., Mansel, R. E., von Minckwitz, G., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62292-8 · Cited by 590
Patient adherence and persistence with oral anticancer treatment
Ruddy, K., Mayer, E., & Partridge, A. (2009) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20004 · Cited by 569 · cited 3×
“Unfortunately, rates of nonadherence to aromatase inhibitors remain disturbingly high, including failure to fill an initial prescription, discontinuation of medication, and also having a Medication Possession Ratio (MPR) of less than 80% [26,27].”
BackgroundSexual function after breast cancer
Panjari, M., Bell, R. J., & Davis, S. R. (2011) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2010.02034.x · Cited by 234
Livaudais, J. C., Hershman, D. L., Habel, L., Kushi, L., Gomez, S. L., Li, C. I., Neugut, A. I., Fehrenbacher, L., Thompson, B., & Coronado, G. D. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1762-1 · Cited by 93 · cited 1×
“Socioeconomic factors such as ethnicity, income, education, and marital status have not been strong or consistent predictors [31].”
BackgroundCastel, L. D., Hartmann, K. E., Mayer, I. A., Saville, B. R., Alvarez, J., Boomershine, C. S., Abramson, V. G., Chakravarthy, A. B., Friedman, D. L., & Cella, D. F. (2013) · Cancer · doi:10.1002/cncr.28016 · Cited by 43
Cited by
Hummel, S. B., van Lankveld, J. J. D. M., Oldenburg, H. S. A., Hahn, D. E. E., Kieffer, J. M., Gerritsma, M. A., Kuenen, M. A., Bijker, N., Borgstein, P. J., Heuff, G., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.6021 · Cited by 162
Nestoriuc, Y., von Blanckenburg, P., Schuricht, F., Barsky, A. J., Hadji, P., Albert, U.-S., & Rief, W. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw266 · Cited by 103
Toivonen, K., Williamson, T., Carlson, L., Walker, L., & Campbell, T. (2020) · Cancers · doi:10.3390/cancers13010107 · Cited by 77
Long-Term Effects of Breast Cancer Therapy and Care: Calm after the Storm?
Tommasi, C., Balsano, R., Corianò, M., Pellegrino, B., Saba, G., Bardanzellu, F., Denaro, N., Ramundo, M., Toma, I., Fusaro, A., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11237239 · Cited by 76
Hummel, S. B., van Lankveld, J. J., Oldenburg, H. S., Hahn, D. E., Broomans, E., & Aaronson, N. K. (2015) · BMC Cancer · doi:10.1186/s12885-015-1320-z · Cited by 64
Metadata
- Authors
- Schover, L. R., Baum, G. P., Fuson, L. A., Brewster, A., & Melhem-Bertrandt, A.
- Venue
- The Journal of Sexual Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-12-01
- Volume
- 11
- Issue
- 12
- Pages
- 3102-3111
- ISSN
- 1743-6095 (ISSN-L)
- 1743-6109
- OpenAlex
- W2103309742
- Cited by
- 112
- References
- 10
- FWCI
- 7.64
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.